title: A case of Hodgkin's lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD.
abstract: Hodgkin's lymphoma (HL) originates from clonal B cells and is the most common malignancy in the second decade of life. Liver involvement is uncommon at presentation in patients with HL and there is a paucity of data for treatment of patients with severely impaired liver function. We present an unusual case of HL with severe hepatic impairment, splenomegaly and multiple chromosomal abnormalities that was treated initially with gemcitabine and steroids. Once liver function tests improved, six cycles of Adriamycin, bleomycin, vinblastine, and dacarbazine were administered. The patient remains in remission at 3.5 years of follow-up.
authors.affiliation: Hospitalist Services, Essentia Health, Brainerd, MN, USA.
authors.forename: Rajshekhar
authors.initials: R
authors.lastname: Chakraborty
authors.affiliation: Department of Internal Medicine, Queens Hospital Center (Affiliated Icahn School of Medicine at Mount Sinai), Jamaica, NY, USA.
authors.forename: Shiva Kumar Reddy
authors.initials: SK
authors.lastname: Mukkamalla
authors.affiliation: Department of Internal Medicine, Queens Hospital Center (Affiliated Icahn School of Medicine at Mount Sinai), Jamaica, NY, USA.
authors.forename: Garfield
authors.initials: G
authors.lastname: Gutzmore
authors.affiliation: Department of Internal Medicine, Queens Hospital Center (Affiliated Icahn School of Medicine at Mount Sinai), Jamaica, NY, USA.
authors.forename: Hon Cheung
authors.initials: HC
authors.lastname: Chan
keywords: cytogenetics; hepatomegaly; remission
references.citation: Genes Chromosomes Cancer. 1991 Jul;3(4):294-9
references.pmid: 1958594
references.citation: Gastroenterol Hepatol. 2005 May;28(5):275-8
references.pmid: 15871809
references.citation: J Clin Oncol. 2000 Jul;18(14):2780-7
references.pmid: 10894879
references.citation: Ann Oncol. 2003 Dec;14(12):1762-7
references.pmid: 14630682
references.citation: Blood. 2009 Oct 29;114(18):3970-1; author reply 3971-2
references.pmid: 19875526
references.citation: Leuk Lymphoma. 2010 Aug;51(8):1523-9
references.pmid: 20578815
references.citation: Cancer. 1973 Apr;31(4):840-7
references.pmid: 4267529
references.citation: Cancer Res. 2006 Nov 1;66(21):10332-8
references.pmid: 17079453
references.citation: Cancer. 1975 Jul;36(1):252-9
references.pmid: 54209
references.citation: Clin Lymphoma Myeloma. 2009 Apr;9(2):167-70
references.pmid: 19406729
references.citation: N Engl J Med. 1992 Nov 19;327(21):1478-84
references.pmid: 1383821
references.citation: Arch Intern Med. 1962 Dec;110:872-83
references.pmid: 14014505
references.citation: Eur J Gastroenterol Hepatol. 2008 Feb;20(2):145-7
references.pmid: 18188038
references.citation: J Clin Oncol. 2000 Jul;18(13):2615-9
references.pmid: 10893294
references.citation: Korean J Hepatol. 2005 Jun;11(2):164-8
references.pmid: 15980675
references.citation: Cancer Res. 1971 Nov;31(11):1811-3
references.pmid: 5121687
references.citation: Semin Liver Dis. 1987 Aug;7(3):269-77
references.pmid: 3317863
references.citation: Leuk Lymphoma. 2013 May;54(5):973-8
references.pmid: 23025342
references.citation: Ann Oncol. 2007 Jun;18(6):1071-9
references.pmid: 17426059
references.citation: Leuk Lymphoma. 2010 May;51(5):947-51
references.pmid: 20367133
references.citation: Natl Cancer Inst Monogr. 1973 May;36:291-301
references.pmid: 4744588
references.citation: Blood. 2003 May 1;101(9):3681-6
references.pmid: 12511414